RxDoctor Payments DataLook up a doctor →

Sarah Jewell, MD

Hematology & Oncology · Heber Springs, ARNPI 1508152471

Payments from drug & device makers

$6,386in general payments, 2019–2025

Across 408 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$684
  • Novartis$598
  • Bristol Myers Squibb$461
  • AstraZeneca$382
  • Regeneron Healthcare Solutions, Inc.$351
  • Amgen$316
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)38$684
Novartis32$598
Bristol Myers Squibb42$461
AstraZeneca24$382
Regeneron Healthcare Solutions, Inc.21$351
Amgen18$316
Merck20$284
Jazz Pharmaceuticals Inc.15$232
Gilead(2 entities)9$201
Eisai Inc.14$196
Lilly USA, LLC12$195
Takeda Pharmaceuticals U.S.A., Inc.11$187
Ipsen Biopharmaceuticals, Inc11$157
Boehringer Ingelheim8$150
Daiichi Sankyo Inc.9$143
Foundation Medicine, Inc.5$129
Sanofi6$94
Sumitomo Pharma America, Inc.4$90
Astellas Pharma US Inc6$86
E.r. Squibb & Sons, L.L.C.6$85
Pfizer6$80
Genentech USA, Inc.4$78
G1 Therapeutics, Inc.5$77
Dendreon Pharmaceuticals LLC5$70
Tersera Therapeutics LLC4$68
GSK5$64
Blueprint Medicines Corporation4$63
Rigel Pharmaceuticals, Inc.5$62
Puma Biotechnology, Inc.4$56
EMD Serono, Inc.3$55
Exelixis Inc.3$51
Bayer3$44
Seagen Inc.3$38
Genmab U.S., Inc.2$35
Kyowa Kirin, Inc.3$35
Beigene USA, Inc.2$30
AVEO Pharmaceuticals, Inc.2$29
Array Biopharma Inc2$29
Blue Earth Diagnostics2$29
Clovis Oncology, Inc.3$27
Karyopharm Therapeutics Inc.2$25
Pharmaessentia USA Corporation2$25
AbbVie2$25
Agios Pharmaceuticals, Inc.2$24
Heron Therapeutics, Inc.2$24
Secura Bio, Inc.2$19
Lexicon Pharmaceuticals, Inc.1$16
Global Blood Therapeutics, Inc.1$15
Iovance Biotherapeutics, Inc.1$15
Sobi, Inc1$14
Deciphera Pharmaceuticals Inc.1$14
CTI Biopharma Corp.1$14
Servier Pharmaceuticals LLC1$13
Menarini Silicon Biosystems, Inc.1$13
Portola Pharmaceuticals, LLC1$13
Taiho Oncology, Inc.1$13
Myovant Sciences Inc.1$13
TG Therapeutics, Inc.1$13
Incyte Corporation1$12
ADC Therapeutics America, Inc.1$12

How this compares

$6,386 in reported general payments places this provider in the 45th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$6,550,646
Medicare patients
1,608
Services billed
292,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Heber Springs

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →